EE291 Budget Impact Analysis of Mrna-1273 (Spikevax) in Patients with COVID-19 in Bulgaria
Vaccination is the safest and most effective means of preventing COVID-19 and limiting the spread of the causative virus (SARS-CoV-2). Currently, more than 100 SARS-CoV-2 vaccines are in clinical trials and 24 are approved for use. Following the introduction and mass administration of vaccines approved in the European Union, there has been a strong reduction in the number of severe COVID-19 variants and deaths worldwide. The primary objective of this study was to evaluate the budget impact (BI) of the pharmacoeconomic performance of COVID-19 vaccine prophylaxis medicines in Bulgaria.
Source: Value in Health - Category: International Medicine & Public Health Authors: A. Dacheva, M. Boyan Likomanov, G. Slavchev, Y. Vutova, S. Djambazov Source Type: research
More News: Budgets | Bulgaria Health | Clinical Trials | Covid Vaccine | COVID-19 | International Medicine & Public Health | SARS | Study | Vaccines